Reynolds American Stock To Go Ex-dividend Tomorrow (RAI)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- The ex-dividend date for Reynolds American (NYSE: RAI) is tomorrow, September 6, 2012. Owners of shares as of market close today will be eligible for a dividend of 59 cents per share. At a price of $46.37 as of 9:30 a.m. ET, the dividend yield is 5.1%.

The average volume for Reynolds American has been 2.1 million shares per day over the past 30 days. Reynolds American has a market cap of $26.07 billion and is part of the consumer goods sector and tobacco industry. Shares are up 11.3% year to date as of the close of trading on Tuesday.

Reynolds American Inc., through its subsidiaries, manufactures and sells cigarette and other tobacco products in the United States. The company has a P/E ratio of 19, above the average tobacco industry P/E ratio of 18.2 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Reynolds American as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Reynolds American Ratings Report.

See our dividend calendar or top-yielding stocks list.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing